Over the last 12 months, Arcus Biosciences insiders reported no purchases and 23 sales totaling $14.2M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 2,827 | $30 | $85K | -6.7% | plan |
| Jul 10, 2026 | Jaen Juan C.President · O | ▼ Sale | 68,569 | $29.63 | $2.0M | -7.7% | plan · 3 tranches · indirect |
| Jun 24, 2026 | Jaen Juan C.President · O | ▼ Sale | 31,431 | $27.92 | $878K | -3.4% | plan · 4 tranches · indirect |
| Jun 1, 2026 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 2,562 | $25.77 | $66K | -6.1% | plan |
| Jan 5, 2026 | Jaen Juan C.President · O | ▼ Sale | 31,823 | $21.41 | $681K | -3.3% | plan · 3 tranches · indirect |
| Dec 31, 2025 | Goeltz II Robert C.Chief Financial Officer · O | ▼ Sale | 6,552 | $23.38 | $153K | -8.8% | plan |
| Dec 18, 2025 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 8,832 | $22.13 | $195K | -32.3% | plan · 3 tranches |
| Dec 17, 2025 | Markus RichardChief Medical Officer · O | ▼ Sale | 9,546 | $22.01 | $210K | -12.7% | plan · 2 tranches |
| Dec 17, 2025 | Tang Carolyn C.General Counsel · O | ▼ Sale | 14,468 | $22.01 | $318K | -10.4% | plan · 2 tranches |
| Dec 17, 2025 | Jarrett JenniferChief Operating Officer · O | ▼ Sale | 21,208 | $22.01 | $467K | -9.9% | plan · 2 tranches |
| Dec 17, 2025 | Goeltz II Robert C.Chief Financial Officer · O | ▼ Sale | 12,662 | $22.01 | $279K | -14.5% | plan · 2 tranches |
| Dec 17, 2025 | Jaen Juan C.President · O | ▼ Sale | 21,208 | $22.01 | $467K | -5.8% | plan · 2 tranches |
| Dec 17, 2025 | ROSEN TERRY JChief Executive Officer · O·D | ▼ Sale | 54,691 | $22.01 | $1.2M | -2.4% | plan · 2 tranches |
| Dec 4, 2025 | Jaen Juan C.President · O | ▼ Sale | 82,997 | $24.71 | $2.1M | -8% | plan · indirect |
| Nov 26, 2025 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 1,900 | $26 | $49K | -6.5% | plan |
| Nov 26, 2025 | Goeltz II Robert C.Chief Financial Officer · O | ▼ Sale | 5,000 | $25 | $125K | -5.4% | plan |
| Nov 18, 2025 | Jaen Juan C.President · O | ▼ Sale | 50,000 | $20.26 | $1.0M | -4.6% | plan · 3 tranches · indirect |
| Nov 7, 2025 | Jarrett JenniferChief Operating Officer · O | ▼ Sale | 50,291 | $18.97 | $954K | -19% | plan |
| Oct 30, 2025 | Jaen Juan C.President · O | ▼ Sale | 4,314 | $20.32 | $88K | -0.4% | plan · indirect |
| Oct 29, 2025 | Jaen Juan C.President · O | ▼ Sale | 96,859 | $20.76 | $2.0M | -8.2% | plan · 4 tranches · indirect |
| Oct 28, 2025 | Goeltz II Robert C.Chief Financial Officer · O | ▼ Sale | 5,000 | $20 | $100K | -5.1% | plan |
| Oct 8, 2025 | Jarrett JenniferChief Operating Officer · O | ▼ Sale | 50,292 | $14.92 | $750K | -19% | plan · 2 tranches |
| Sep 29, 2025 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 2,831 | $13 | $37K | -9.4% | plan |
| Sep 5, 2025 | Azoy AlexanderChief Accounting Officer · O | ▼ Sale | 1,579 | $11.88 | $19K | -5% | plan |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Arcus Biosciences filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RCUS feed.